Objective: Obstructive sleep apnoea (OSA) occurs frequently in obese patients and may be reversible with weight loss. Obstructive sleep apnoea and obesity are both independent risk factors for hypertension and increased sympathetic activity. Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension. No studies have investigated the effect of sibutramine on OSA, blood pressure and heart rate. We aimed to assess the changes in OSA and cardiovascular parameters in obese men with OSA enrolled in a sibutramine-assisted weight loss programme (SIB-WL). Design: Open uncontrolled cohort study of obese male subjects with OSA in an SIB-WL. Subjects: Eighty-seven obese (body mass index ¼ 34.272.8 kg/m 2 ) middle-aged (46.379.3 years) male subjects with symptomatic OSA (Epworth score 13.473.6; respiratory disturbance index (RDI) 46.0723.1 events/h) completed the study. Results: At 6 months, there was significant weight loss (8.374.7 kg, Po0.0001), as well as a reduction in waist and neck circumference and sagittal height (all Po0.0001). These changes were accompanied by a reduction in OSA severity (RDI fell by 16.3719.4 events/h and Epworth score by 4.574.6), both Po0.0001). There was no significant change to systolic (P ¼ 0.07) or diastolic blood pressure (P ¼ 0.87); however, there was a mild rise in resting heart rate (Po0.0001). Conclusion: Moderate (B10%) weight loss with SIB-WL results in improvement in OSA severity without increase in blood pressure in closely monitored OSA subjects.
Introduction
Obstructive sleep apnoea (OSA) is a disease characterised by loud snoring and repetitive closure of the upper airway during sleep. The increasing respiratory efforts to overcome airway closure lead to arousals from sleep and fragmentation of normal sleep patterns with the subsequent development of excessive daytime sleepiness (EDS). 1 About 25% of middleaged men and 9% of middle-aged women have OSA (defined as an apnoea -hypopnoea index greater than 5 events/h). 2 Obstructive sleep apnoea syndrome (OSAS), defined by OSA with significant EDS, occurs in 2 and 4% of middle-aged women and men, respectively. 3 Obesity is commonly associated with OSA and has been shown to increase the risk of OSA 10-fold when compared to subjects with normal weight. 4 Indeed, most patients with OSA are obese 5 and at least 50% of severely obese patients report symptoms of OSA. 6 Obesity predisposes individuals to OSA by reducing upper airway size presumably owing to enlargement of lateral airway fat pads and lateral pharyngeal walls. 7 In addition, abdominal obesity may further compound airway collapsibility secondary to a reduction of lung volumes, particularly in the supine position. 8 Although obesity is a well-established risk factor for cardiovascular morbidity and mortality, coexistent OSA is likely to increase this risk. 9, 10 Indeed, OSA is an established risk factor for the development of hypertension independent of obesity and is associated with difficulty to control blood pressure 11 and left ventricular hypertrophy. 12 Therapies that immediately prevent airway obstruction such as nasal continuous positive airway pressure (CPAP), mandibular advancement splints (MAS) and upper airway surgery currently form the primary treatment modality for OSA with clinical advice about the more long-term benefits of weight loss having a secondary role. The efficacy of CPAP treatment in OSA is well established, but adherence is generally suboptimal. 13 Mandibular advancement splints and surgery have variable and less convincing efficacy in moderate to severe forms of OSA and no therapy (including CPAP) appears to have an impact on obesity. 1 In contrast, studies that have involved surgical or dietary-assisted weight loss have demonstrated significant improvements in associated OSA 14, 15 Although these studies have been confined to morbidly obese and/or small-sized cohorts, they highlight the need to more comprehensively assess the effects of weight loss over a larger body mass index (BMI) and OSA severity range.
There is considerable evidence that use of weight-reducing medications increases weight loss in patients on diet programmes. 16 Sibutramine hydrochloride, an orally administered serotonin (5-hydroxytryptamine, 5HT) and noradrenaline re-uptake inhibitor (SNRI), has been shown to induce dose-dependent weight loss and to enhance the effects of a low calorie diet and exercise programme. Sibutramine appears to have a more positive effect on the reduction in central adiposity, 17 a common phenotypic feature of OSA, than general obesity. There have been no studies that have specifically assessed the effects of pharmacologically induced weight loss in OSA and no weight loss studies have included appreciable numbers of subjects with a wide range of obesity and OSA severity to define clearly the relationship between weight loss and OSA alleviation. Only one study has documented that, in the absence of weight loss, short-term use of sibutramine does not alter sleep apnoea severity. 18 However, concerns have been raised about potential adverse cardiovascular effects of sibutramine. While dietinduced weight loss is associated with a fall in blood pressure, 19 the effects from sibutramine are less clear. 20, 21 Given that OSA is a risk factor for hypertension 22 and difficult to control blood pressure, 11 there may be specific concerns in using sibutramine in obese patients with OSA. It is possible that sibutramine may initially increase blood pressure in subjects with OSA at least in the early stages of use before weight loss occurs. In addition, given that OSA is associated with increased heart rate, 23 the well-documented increase in heart rate associated with the use of sibutramine 16 may be important to monitor in these patients.
Hence, this present study substantially replicates the open phase of the initial Phase 3 sibutramine study 24 in an uncontrolled cohort design and was undertaken to provide within-subject data on the impact of sibutramine-assisted weight loss (SIB-WL) in a male population on sleep apnoea , blood pressure and heart rate.
Subjects and methods
The study was approved by the Ethics Review Committee (RPAH zone) of the Central Sydney Area Health Service (protocol number X020316). Subjects were excluded at screening if they had labile hypertension or inadequately controlled hypertension defined as blood pressure 4145/95 mm Hg or a heart rate 4100 beats per minute (b.p.m.) after 15 min rest in the sitting position. These blood pressure limits were set marginally higher than the traditional 140/90 mm Hg to maximise recruitment in a population where the prevalence of hypertension is higher than expected. Most subjects were newly diagnosed with sleep apnoea and were CPAP naïve. Nine subjects had previously trialled CPAP therapy without success. None of these subjects had used CPAP in the 6 months before enrollment. Other exclusion criteria were similar to previously published sibutramine weight loss trials. 24 Subjects who satisfied the eligibility criteria were enrolled into the 24-week open sibutramine-assisted weight loss programme. The energy requirements for each subject were estimated by using the Harris Benedict equation for men. After the determination of daily energy requirements and collection of a detailed diet history by a dietician, subjects were prescribed a 2500 kJ (À600 kcal) deficit daily diet, based on a macronutrient content o30% fat (with emphasis on reducing saturated fat in the diet), 15% protein and at least 55% carbohydrate. Advice was also given on behavioural modification and increased activity in the form of at least 30 min brisk walking per day. Subjects were given 10 mg of sibutramine once daily to be taken in the morning with or without food. Subjects who exhibited inadequate weight loss (o2 kg) in the first month of the trial were prescribed 15 mg sibutramine daily for the remainder of the trial.
Study population

Anthropometrics
All anthropometric measurements were performed in duplicate using standardised techniques. 25 Height was measured (70.1 cm) at mid-inspiratory level using a stadiometer. Subjects were weighed (70.1 kg) on a digital scale after voiding and without shoes. Body mass index was calculated as weight (kg) divided by height squared (m 2 ). Waist circumference (70.1 cm) was measured at the narrowest point between the lower costal border and the iliac crest. Neck
Effect of sibutramine-assisted weight loss BJ Yee et al circumference and sagittal diameter were also measured using standard techniques. 25 Anthropometric variables were used to estimate visceral fat with equations that have been previously validated from computed tomography (CT) assessment. 6 Anthropometric measurements were conducted at baseline and 24 weeks.
Sleep study/polysomnography A standard PSG (Compumedics, Melbourne, Australia) was performed in all subjects at baseline and 24 weeks. The electroencephalograph (EEG) leads were placed according to the 10-20 system with four electrodes attached to the scalp (C3, O2, A1 and A2), two eye electrodes (EOGL and EOGR) and two submental leads (EMG). There were also two electrocardiograph (ECG) leads, one near the right shoulder and a second in the sixth intercostal space on the left-hand side of the chest. Sensor leads were placed on each leg over the anterior tibialis for recording leg movements. A nasal pressure transducer monitored breathing via nasal cannula. Inductive respiratory bands were placed around the chest and abdomen to monitor thoracic and abdominal wall movement. A position sensor was attached to monitor body position during sleep. A finger probe oximeter recorded the subjects' oxygen saturation continuously. Sleep stages were scored according to standard criteria. 26 Arousals were scored according to the Atlas Task Force of the American Sleep Disorders Association. 27 For scoring of respiratory events, thoracic and abdominal bands and nasal pressure were used as measures of breathing. An apnea was defined as cessation of airflow for X10 s (with or without a 3% oxygen desaturation or arousal) and a hypopnoea was defined as a clear reduction (420%, compared with the baseline over the preceding 2 min) in one of the measures of breathing during sleep for X10 s in association with a X3% oxygen desaturation and/or an EEG arousal. The total respiratory disturbance index was defined by the number of apnoeas plus hypopneas per hour of sleep. The REM RDI was the number of apnoeas and hypopneas in rapid eye movement (REM) sleep. The NREM RDI was the number of apnoeas and hypopneas in non-REM (NREM) sleep. Oxygen time less than 90% is defined as total sleep time less than 90% oxygen saturation. All studies were scored blinded.
Questionnaires At baseline and 24 weeks, subjects were given the Epworth Sleepiness Scale (ESS) questionnaire, a validated instrument that measures daytime sleepiness. 28 The normal community mean score is 4.073 (s.d.) with unequivocal EDS defined as an ESS 410.
Blood pressure and heart rate monitoring Blood pressure and heart rate were monitored every 2 weeks for the first 3 months and then on a monthly basis after week 12. Blood pressure was measured in the seated position from the non-dominant arm after 15 min rest in triplicate. Pressures were determined by sphygmomanometry and/or by an automated oscillometric device (Omron T5 BP monitor -Omron Healthcare Inc., Kyoto, Japan) with appropriate sized blood pressure cuffs. Pulse rates were determined from the automatic device. Patients were withdrawn from the study if they had an increase, over 1 month or more, in systolic/diastolic blood pressure above 145/95 mm Hg.
Patients were also withdrawn if systolic/diastolic blood pressure exceeded 160/100 mm Hg or if heart rate exceeded 120 b.p.m. at a single visit.
Statistical analysis
Individual paired anthropometric, ESS questionnaire and PSG results were assessed using parametric paired student's t tests and non-parametric Wilcoxon's signed-rank tests as appropriate. Multiple linear regressions were used to investigate the relationship between weight loss and other sleep-related variables to the improvement in sleep apnoea severity (RDI). Predictor variables that were found to violate the co-linearity assumption were analysed separately. Respiratory disturbance index was normally distributed. Repeated measures analysis of variance was used to assess blood pressure and heart rate data. Mauchly's test of sphericity was applied with the Huynh-Feldt correction for degrees of freedom, where appropriate. The SPSS statistical software (Chicago, IL, USA) was used for all statistical analyses. A P-value of less than 0.05 was considered statistically significant and all tests were two-tailed.
Results
Ninety-three male subjects were initially recruited. Six subjects withdrew from the study voluntarily owing to work or family commitments and non-compliance with the protocol. One subject did not have anthropometric measurements performed at 24 weeks owing to work commitments and was excluded from all anthropometric analyses. Twenty-three subjects required an increased dose of sibutramine (to 15 mg) because of inadequate weight loss (o2 kg) in the first month. There were 26 subjects (30%) who were taking antihypertensive medication, including four who had poorly controlled hypertension before the study but were later enrolled when their blood pressure was well controlled. Importantly, there were no subjects withdrawn because of constantly sustained hypertension. One subject was withdrawn owing to the development of a resting tachycardia during the study. An ECG subsequently revealed a sinus tachycardia that resolved upon withdrawal from the drug and study. Table 1 shows the baseline to 24-week comparison of anthropometric, polysomnographic and ESS data. The study subjects were middle aged (46.379.3 years) and obese with the evidence of moderate to severe OSAS. After 24 weeks with SIB-WL, there was a fall in weight by 8.374.7 kg Effect of sibutramine-assisted weight loss BJ Yee et al amounting to 7.874.2% of total body weight. This was accompanied by significant improvements in subjective (ESS) and objective (RDI, NREM RDI, REM RDI, sleep time SaO 2 o90%) markers of OSA. Weight loss occurred in 84 of the 86 subjects who completed the study (Figure 1 ). Of the subjects who lost weight, the proportion of subjects who lost o5%, 5-10 and 410% of total body weight was 26, 44 and 30%, respectively. Seventy of the 87 (B80%) subjects had a reduction in RDI as demonstrated by the subjects below the line of identity in Figure 2 . Of these, the proportion of subjects who had o25, 25-50 and 450% reduction were 23, 34 and 43%, respectively. By the end of the trial, four subjects had an RDIo5 events/h, including one subject with prior severe OSA.
There was a significant correlation between % change in RDI and % change in weight (Figure 3) . A subsequent regression analysis (Table 2 ) demonstrated that anthropometric changes were the dominant factors determining a reduction in sleep disordered breathing. However, the best model, incorporating % change in total body weight only accounted for a quarter of the variance. In this model, the combined effects of changes in the amount of REM and supine sleep (which predispose to an increase in sleep disordered breathing) were less than half of that attributed to the change in weight.
Blood pressure and heart rate data are presented in Figure 4 . Bi-monthly values represent means for all visits during each 2-month period. Follow-up data were recorded in 69 subjects 1 week after sibutramine intake had ceased. There was no overall change in systolic or diastolic blood pressure during the 6 months SIB-WL; however, systolic pressure did show a trend for a fall (P ¼ 0.07). Despite this, there were individuals who developed transient elevations in blood pressure (415 mm Hg) that were sustained for at least 1 month. Three subjects had increases in systolic blood pressure and one of these subjects and two others also developed a similar rise in diastolic blood pressure. It is important to note, however, that during these periods, the average pressure did not exceed the limits that define clinical hypertension (140/90 mm Hg) for any of these subjects. In contrast to group blood pressure, there was a significant rise in heart rate Effect of sibutramine-assisted weight loss BJ Yee et al (Figure 4 ), including 20 subjects who had transient rises (415 b.p.m.) that were sustained for at least 1 month. The maximum sustained rise in any one subject occurred at weeks 6, 8 and 10, where heart rates increased from 80 (at baseline) to 103, 100 and 105 before falling again by week 12. Overall, heart rate changes were unrelated to weight loss (P ¼ 0.86) or to changes in RDI (P ¼ 0.75).
Discussion
This study demonstrates that modest weight loss in obese male subjects with moderate to severe OSA provides improvements in both subjective sleepiness and objective measures of sleep disordered breathing. The magnitude of improvement in OSA was associated with the degree of weight loss. These findings are consistent with previous small studies of diet-induced or surgical weight loss in OSA. 15 Although subjects in this study achieved only modest weight loss compared with surgical weight loss studies, by including a large number of subjects with moderate degrees of obesity, the data provide a more comprehensive assessment of the effects of weight loss in a cohort of subjects with a wide range of OSA severity. Virtually all subjects were able to lose weight during the study and a vast majority of subjects had a decrease in RDI. Change in total body weight explained 25% of the variance in RDI and the explanatory power of change in weight was greater than change in neck circumference or visceral adipose tissue estimated using CT calibrated equations with sagittal diameter measurements. 6 The reduction in obstructive apnoeas (in both NREM and REM sleep) versus hypopneas (NREM sleep) was similar in magnitude. Although this suggests that both apnoeas and hypopneas resolve equally in response to weight loss, there were relatively few individuals Figure 4 Mean bi-monthly trend for blood pressure and heart rate. P-values represent effect across time for each variable. Heart rate was significantly higher than baseline for all other time points (Po0.0001)
Effect of sibutramine-assisted weight loss BJ Yee et al who demonstrated a predominance of apnoeas or a predominance of hypopneas in isolation. Consequently, we were unable to determine whether there was a bias for a greater resolution of sleep disordered breathing in individuals with predominantly partial (hypopnea) versus complete (apnoea) related upper airway obstruction. It is clear that other factors may be more closely related to the improvement in RDI observed in this group. These include changes in upper airway size in relation to changes in lateral pharyngeal fat pad volume and/or pharyngeal wall thickness, measures that are only obtainable with more detailed imaging techniques. 7 In addition, on the basis of this study design, we cannot exclude an independent effect of sibutramine on both RDI and sleepiness. In the short term, drugs with similar neuropharmacological actions as sibutramine have been shown to result in modest improvements in RDI in patients with OSA. 29 Furthermore, the clear improvement in sleepiness associated with weight loss in the present study could conceivably be related to an alerting effect of sibutramine. 30 However, a recent study which specifically assessed the acute effects of sibutramine over a 1-month period without weight loss did not find any change in sleep architecture or the severity of sleep disordered breathing. 18 In contrast to the majority of subjects who had a decrease in RDI, there is no clear reason for the increase in RDI in 17 subjects, including no increase in either REM sleep or supine sleep. However, 14 of these subjects had only a minimal increase in RDI that is within the mild degree of night-to-night variability observed previously in OSA. 2 At the time of study commencement, concerns had been raised about the use of sibutramine in obese patients with hypertension, including those on treatment. 31 Given the high prevalence of hypertension in patients with OSA, 32 and the causative role that OSA may play in this hypertension, 33, 34 it was considered more meaningful to first establish whether theoretical concerns about the risk of sibutramine use in OSA were valid. Importantly, despite these concerns, there was no overall rise in blood pressure in this study and no patients developed overt hypertension (BP 4140/90 mm Hg). It is interesting to note that there was a tendency for systolic blood pressure to fall during sibutramine intake and then rise back to baseline levels after drug washout. This finding is in keeping with the inhibitory clonidine-like effect of sibutramine on the central nervous system. 35, 36 In contrast to blood pressure however, the overall changes in heart rate seen in the study were approximately twice those reported in other placebo-controlled trials. 21 This difference may relate to gender bias (all subjects in the current study were male) or enhanced sympathetic activity secondary to the combined effects of moderate-severe sleep apnoea 37 and sibutramine. However, the clinical significance of the small heart rate rise observed in this study is not clear despite the known cardiovascular risk associated with an elevated resting heart rate. 38 Finally, the fact that some individuals in the study cohort developed transiently sustained rises (for at least 1 month) in one or more of systolic/diastolic blood pressure (415 mm Hg) and/or heart rate (415 b.p.m.), highlights the need for vigilant monitoring of cardiovascular parameters in individuals taking this drug. Although it is reassuring from a safety perspective that blood pressure did not increase with SIB-WL, it appears that any beneficial effects from a reduction of RDI on blood pressure did not occur. Several studies have demonstrated that complete elimination of OSA with CPAP reduces blood pressure, 33, 34 an effect that is particularly pronounced in OSA subjects with drug-resistant hypertension. 39 Given that SIB-WL only achieved partial resolution of OSA in the present study and that patients with persistent hypertension were excluded, any beneficial effects may not have occurred within this time frame. Alternatively, there may have been beneficial effects that were masked by sibutramine secondary to peripheral norepinephrine re-uptake inhibition. 35 The gold standard treatment for OSA is CPAP, which under optimal conditions of compliance, is a highly effective treatment modality. However, CPAP is known to be associated with variable compliance rates of only 25-80% even in severe symptomatic patients. 40 Patients who reject CPAP have limited options. Mandibular advancement splints have recently been shown to be useful for only mild to moderate OSA, 41 and their limited effectiveness (70% of patients only have a partial improvement in their OSA) is difficult to predict. Palatal surgery also has variable results. 42 Although, bariatric surgery is very successful at reducing large amounts of weight, it is generally not considered appropriate for patients with moderate obesity. Hence, any subjective or objective improvements in OSAS patients that result with these treatment options may in the very least be no better than those associated with SIB-WL. Furthermore, given that there are also beneficial metabolic effects following weight loss with sibutramine, 43 the overall outcome improvement in OSAS patients may in some cases be better than established therapies with poor compliance. One clear limitation of our study was that in order to focus on monitoring potential cardiovascular risk with sibutramine, an open design was used instead of a randomised placebo-controlled design. However, there have been numerous placebo-controlled studies with sibutramine and the effects of placebo pills in randomised-controlled trials aimed at assessment of CPAP effectiveness have also been quantified. 44 Interestingly, the improvement in ESS in the present study was more than twice that reported for 'sham' CPAP devices or placebo pills. 44 Nevertheless, it will be important to confirm these findings with placebo-controlled studies or even perform a randomised study comparing CPAP and placebo with sibutramine to investigate the role of SIB-WL in the current treatment of OSAS. This is the first pharmacologically assisted weight loss study in a large group of male symptomatic sleep apnoea subjects. Weight loss was successful in almost every subject recruited and was accompanied by an overall reduction in subjective and objective OSA severity. Apart from one subject who had a mild adverse event, there were no other Effect of sibutramine-assisted weight loss BJ Yee et al significant complications during the study. We did not find any significant change in blood pressure in the group as a whole, although heart rate did have a modest increase. These data demonstrate that in closely monitored patients, sibutramine can be used effectively as a weight loss agent in OSAS and results in improvement in sleep disordered breathing and symptoms. Pending confirmation by randomisedcontrolled trials, these findings have important clinical implications in terms of management of OSA patients who may not be compliant or tolerant to currently available therapies.
